During Nvidia (NASDAQ:NVDA)'s 2024 GPU Technology Conference (GTC), while the spotlight was on the latest AI chip and Blackwell platform, the company also emphasized the wide-ranging potential of AI in sectors like drug development, medical technology, and consumer health.
New software tools introduced by Nvidia aim to boost the adoption of generative AI, especially within the biopharmaceutical industry, and among physicians and hospitals, by making the technology easier to use.
A key new offering, Nvidia Inference Microservices (NIM), is designed to facilitate the local implementation of ready-to-use and optimized AI models, enhancing the flexibility that companies have in managing their applications and sensitive data.
The chipmaker highlighted Amgen and Recursion Pharmaceuticals as users of its microservices and pointed out its collaborations with Johnson & Johnson MedTech and Novo Nordisk, among others.
“Per our diligence and KOL discussions, integrating AI into existing workflows is a key bottleneck given challenges such as siloed systems, privacy concerns, lack of understanding, and antiquated or limited computing power/technology,” said analysts.
“We further note NVDA’s continued enthusiasm for healthcare as a key vertical and are also monitoring initiatives and commentary from AMZN, MSFT and GOOGL,” they added.
Among the healthcare-related offerings mentioned was Nvidia Clara, the company’s healthcare platform, which has applications in smart sensors, AI imaging, and genomics.
Moreover, the tech giant has also developed tools like BioNeMo and Parabricks, aimed at enhancing computational biology.
The next step involves packaging these tools into microservices for simpler deployment, offering standardized APIs “to be run across different cloud, data centers and workstations.”